Patient Retention: Quality Of Life Is Key

With a dropout rate exceeding 30% in Phase 3 clinical trials, there is a critical need for sponsors to address the challenges that contribute to participant attrition. Sponsors must demonstrate heightened awareness of the burdens imposed on patients, encompassing their health, time, and financial commitments.

Fostering a deeper understanding of the impact on patients' quality of life during the trial becomes paramount in enhancing retention rates. By placing a greater emphasis on monitoring and mitigating the adverse effects on participants' well-being, sponsors can foster a more patient-centric approach. This involves not only focusing on the efficacy of the treatment but also acknowledging and alleviating the practical and emotional challenges faced by individuals throughout the trial process.

Delve into how a conscientious approach to patient welfare can contribute to a more successful and ethical conduct of Phase 3 clinical trials by accessing the article below.